Abstract

The radiopharmaceutical tracer [68Ga] Ga-Prostate-Specific Membrane Antigen (PSMA) has gained recognition for its efficacy in prostate cancer staging and detection, primarily via PSMA Positron Emission Tomography/Computed Tomography (PET/CT). Research has shown that despite its name, PSMA PET/CT is effective in diagnosing and potentially treating various solid tumors other than prostate cancer. These tumors include breast cancer, renal cell carcinoma, glioblastoma multiforme, thyroid cancer, colorectal carcinoma, lung cancer, and follicular lymphoma. HCC, which accounts for the vast majority of primary liver cancer cases, poses diagnostic challenges because it is frequently asymptomatic until advanced stages. Traditional imaging methods, such as Computerized Tomography (CT) or MRI, are important in diagnosis, with PSMA PET/CT demonstrating a high detection rate for HCC. This case report describes an 87-year-old man who was found to have on PSMA PET/ CT prostate cancer and HCC. This case emphasizes the role of PSMA PET/CT in detecting primary liver lesions.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.